Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14


Discovery of Potent Protease-Activated Receptor 4 Antagonists with in Vivo Antithrombotic Efficacy.

Miller MM, Banville J, Friends TJ, Gagnon M, Hangeland JJ, Lavallée JF, Martel A, O'Grady H, Rémillard R, Ruediger E, Tremblay F, Posy SL, Allegretto NJ, Guarino VR, Harden DG, Harper TW, Hartl K, Josephs J, Malmstrom S, Watson C, Yang Y, Zhang G, Wong P, Yang J, Bouvier M, Seiffert DA, Wexler RR, Lawrence RM, Priestley ES, Marinier A.

J Med Chem. 2019 Aug 22;62(16):7400-7416. doi: 10.1021/acs.jmedchem.9b00186. Epub 2019 Aug 5.


Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding.

Wong PC, Seiffert D, Bird JE, Watson CA, Bostwick JS, Giancarli M, Allegretto N, Hua J, Harden D, Guay J, Callejo M, Miller MM, Lawrence RM, Banville J, Guy J, Maxwell BD, Priestley ES, Marinier A, Wexler RR, Bouvier M, Gordon DA, Schumacher WA, Yang J.

Sci Transl Med. 2017 Jan 4;9(371). pii: eaaf5294. doi: 10.1126/scitranslmed.aaf5294.


Synthesis and evaluation of C2-carbon-linked heterocyclic-5-hydroxy-6-oxo-dihydropyrimidine-4-carboxamides as HIV-1 integrase inhibitors.

Naidu BN, Sorenson ME, Patel M, Ueda Y, Banville J, Beaulieu F, Bollini S, Dicker IB, Higley H, Lin Z, Pajor L, Parker DD, Terry BJ, Zheng M, Martel A, Meanwell NA, Krystal M, Walker MA.

Bioorg Med Chem Lett. 2015 Feb 1;25(3):717-20. doi: 10.1016/j.bmcl.2014.11.060. Epub 2014 Nov 27.


Solid phase synthesis of novel pyrrolidinedione analogs as potent HIV-1 integrase inhibitors.

Pendri A, Troyer TL, Sofia MJ, Walker MA, Naidu BN, Banville J, Meanwell NA, Dicker I, Lin Z, Krystal M, Gerritz SW.

J Comb Chem. 2010 Jan-Feb;12(1):84-90. doi: 10.1021/cc9001026.


Changes to the HIV long terminal repeat and to HIV integrase differentially impact HIV integrase assembly, activity, and the binding of strand transfer inhibitors.

Dicker IB, Samanta HK, Li Z, Hong Y, Tian Y, Banville J, Remillard RR, Walker MA, Langley DR, Krystal M.

J Biol Chem. 2007 Oct 26;282(43):31186-96. Epub 2007 Aug 21.


Benzyl amide-ketoacid inhibitors of HIV-integrase.

Walker MA, Johnson T, Naidu BN, Banville J, Remillard R, Plamondon S, Martel A, Li C, Torri A, Samanta H, Lin Z, Dicker I, Krystal M, Meanwell NA.

Bioorg Med Chem Lett. 2007 Sep 1;17(17):4886-90. Epub 2007 Jun 14.


Synthesis and biological evaluation of 4-amino derivatives of benzimidazoquinoxaline, benzimidazoquinoline, and benzopyrazoloquinazoline as potent IKK inhibitors.

Beaulieu F, Ouellet C, Ruediger EH, Belema M, Qiu Y, Yang X, Banville J, Burke JR, Gregor KR, MacMaster JF, Martel A, McIntyre KW, Pattoli MA, Zusi FC, Vyas D.

Bioorg Med Chem Lett. 2007 Mar 1;17(5):1233-7. Epub 2006 Dec 9.


Exploration of the diketoacid integrase inhibitor chemotype leading to the discovery of the anilide-ketoacids chemotype.

Walker MA, Johnson T, Ma Z, Zhang Y, Banville J, Remillard R, Plamondon S, Pendri A, Wong H, Smith D, Torri A, Samanta H, Lin Z, Deminie C, Terry B, Krystal M, Meanwell N.

Bioorg Med Chem Lett. 2006 Nov 15;16(22):5818-21. Epub 2006 Sep 12.


Triketoacid inhibitors of HIV-integrase: a new chemotype useful for probing the integrase pharmacophore.

Walker MA, Johnson T, Ma Z, Banville J, Remillard R, Kim O, Zhang Y, Staab A, Wong H, Torri A, Samanta H, Lin Z, Deminie C, Terry B, Krystal M, Meanwell N.

Bioorg Med Chem Lett. 2006 Jun 1;16(11):2920-4. Epub 2006 Mar 20.


BMS-229724 is a tight-binding inhibitor of cytosolic phospholipase A2 that acts at the lipid/water interface and possesses anti-inflammatory activity in skin inflammation models.

Burke JR, Davern LB, Stanley PL, Gregor KR, Banville J, Remillard R, Russell JW, Brassil PJ, Witmer MR, Johnson G, Tredup JA, Tramposch KM.

J Pharmacol Exp Ther. 2001 Jul;298(1):376-85.


Novel mimics of sialyl Lewis X: design, synthesis and biological activity of a series of 2- and 3-malonate substituted galactoconjugates.

Marinier A, Martel A, Bachand C, Plamondon S, Turmel B, Daris JP, Banville J, Lapointe P, Ouellet C, Dextraze P, Menard M, Wright JJ, Alford J, Lee D, Stanley P, Nair X, Todderud G, Tramposch KM.

Bioorg Med Chem. 2001 Jun;9(6):1395-427.


A beta-lactam inhibitor of cytosolic phospholipase A2 which acts in a competitive, reversible manner at the lipid/water interface.

Burke JR, Gregor KR, Padmanabha R, Banville J, Witmer MR, Davern LB, Manly SP, Tramposch KM.

J Enzyme Inhib. 1998 Jun;13(3):195-206.


Sulfated galactocerebrosides as potential antiinflammatory agents.

Marinier A, Martel A, Banville J, Bachand C, Remillard R, Lapointe P, Turmel B, Menard M, Harte WE Jr, Wright JJ, Todderud G, Tramposch KM, Bajorath J, Hollenbaugh D, Aruffo A.

J Med Chem. 1997 Sep 26;40(20):3234-47.


Structure-activity relationships of carbapenems that determine their dependence on porin protein D2 for activity against Pseudomonas aeruginosa.

Fung-Tomc JC, Huczko E, Banville J, Ménard M, Kolek B, Gradelski E, Kessler RE, Bonner DP.

Antimicrob Agents Chemother. 1995 Feb;39(2):394-9.

Supplemental Content

Loading ...
Support Center